特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

肝性脳症(HE) - 市場洞察、疫学、市場予測

Hepatic Encephalopathy - Market Insight, Epidemiology and Market Forecast - 2030

発行 DelveInsight Business Research LLP 商品コード 534759
出版日 ページ情報 英文 150 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=107.71円で換算しております。
肝性脳症(HE) - 市場洞察、疫学、市場予測 Hepatic Encephalopathy - Market Insight, Epidemiology and Market Forecast - 2030
出版日: 2020年01月01日 ページ情報: 英文 150 Pages
概要

主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)の肝性脳症(HE)の有病数は、2017年に9億1,000万米ドルと推計され、2028年まで増加を続けるとみられています。

当レポートでは、主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)の肝性脳症(HE)市場を調査し、市場および疾患の概要、国別の市場規模、性別・年齢・タイプ別の有病数の推移と予測(通算12年間分)、現行の治療法、上市済み治療薬および新薬の概要、市場の成長要因および障壁、などについてまとめています。

目次

第1章 重要洞察

第2章 肝性脳症(HE)市場の概要

  • 市場シェアと分布状況(実績値)
  • 市場シェアと分布状況(予測値)

第3章 肝性脳症(HE):疾患の背景と概要

  • イントロダクション
  • 分類
  • 症状
  • 危険因子
  • 病態生理
  • 病因
  • 診断
  • 鑑別診断
  • 肝性脳症 2018年:イタリア肝臓研究協会(AISF)の臨床診療ガイドライン

第4章 疫学と患者人口

  • 主な調査結果
  • 調査手法
  • 主要7カ国の肝性脳症(HE)の総有病数
  • 主要7カ国の肝性脳症(HE)の総診断有病数

第5章 肝性脳症の疫学:国別

  • 米国の疫学
    • 仮定と根拠
    • 総有病数
    • 総診断有病数
    • 有病数:性別
    • 有病数:年齢別
    • 有病数:タイプ別
  • 欧州5カ国の疫学
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • 英国

第6章 日本の疫学

  • 仮定と根拠
  • 総有病数
  • 総診断有病数
  • 有病数:性別
  • 有病数:年齢別
  • 有病数:タイプ別

第7章 肝性脳症(HE)の治療と管理

  • 肝性脳症の一連の治療
  • 治療アルゴリズム
  • 治療ガイドライン

第8章 アンメットニーズ

第9章 上市済み治療薬

  • Xifaxan:Salix Pharmaceuticals
    • 製品説明
    • 規制のマイルストーン
    • 研究開発
    • 臨床試験情報
    • 製品プロファイル

第10章 新薬

  • キークロスコンペティション
  • SYNB1020:Synlogic
    • 製品説明
    • その他の開発動向
    • 臨床開発
    • 臨床試験情報
    • 製品プロファイル
  • GR3027:Umecrine Cognition
    • 安全性と有効性
  • MNK-6105 / MNK-6106:Mallinckrodt Therapeutics

第11章 肝性脳症(HE):主要7カ国市場の分析

  • 主な調査結果
  • 主要7カ国の総市場規模
  • 主要7カ国の市場規模:治療薬別

第12章 市場の見通し:米国

  • 米国の市場規模
    • 主要7カ国の総市場規模
    • 主要7カ国の市場規模:現行治療薬・新薬別

第13章 市場の見通し:欧州5カ国

  • ドイツ
    • 総市場規模
    • 市場規模:現行治療薬・新薬別
  • フランス
    • 総市場規模
    • 市場規模:現行治療薬・新薬別
  • イタリア
    • 総市場規模
    • 市場規模:現行治療薬・新薬別
  • スペイン
    • 総市場規模
    • 市場規模:現行治療薬・新薬別
  • 英国

第14章 市場の見通し:日本

  • 総市場規模
  • 市場規模:現行治療薬・新薬別

第15章 市場の成長要因

第16章 市場の障壁

第17章 付録

  • 調査手法

第18章 DelveInsightのサービス内容

第19章 免責事項

第20章 DelveInsightについて

図表

List of Tables

  • Table 1 : 7MM Hepatic Encephalopathy Epidemiology (2017-2030)
  • Table 2 : 7MM Hepatic Encephalopathy Diagnosed and Treatable Cases (2017-2030)
  • Table 3 : Disease% Epidemiology in the United States (2017-2030)
  • Table 4 : Hepatic Encephalopathy Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5 : Hepatic Encephalopathy Epidemiology in Germany (2017-2030)
  • Table 6 : Hepatic Encephalopathy Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7 : Hepatic Encephalopathy Epidemiology in France (2017-2030)
  • Table 8 : Hepatic Encephalopathy Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9 : Hepatic Encephalopathy Epidemiology in Italy (2017-2030)
  • Table 10 : Hepatic Encephalopathy Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11 : Hepatic Encephalopathy Epidemiology in Spain (2017-2030)
  • Table 12 : Hepatic Encephalopathy Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13 : Hepatic Encephalopathy Epidemiology in the UK (2017-2030)
  • Table 14 : Hepatic Encephalopathy Diagnosed and Treatable Cases in the UK (2017-2030)
  • Table 15 : Hepatic Encephalopathy Epidemiology in Japan (2017-2030)
  • Table 16 : Hepatic Encephalopathy Diagnosed and Treatable Cases in Japan (2017-2030)
  • Table 17 : Drug Name, Clinical Trials by Recruitment status
  • Table 18 : Drug Name, Clinical Trials by Zone
  • Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Table 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Table 22 : United States Market Size in USD, Million (2017-2030)
  • Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Table 24 : Germany Market Size in USD, Million (2017-2030)
  • Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Table 26 : France Market Size in USD, Million (2017-2030)
  • Table 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Table 28 : Italy Market Size in USD, Million (2017-2030)
  • Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Table 30 : Spain Market Size in USD, Million (2017-2030)
  • Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Table 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Table 34 : Japan Market Size in USD, Million (2017-2030)
  • Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

List of Figures

  • Figure 1 : 7MM Hepatic Encephalopathy Epidemiology (2017-2030)
  • Figure 2 : 7MM Hepatic Encephalopathy Diagnosed and Treatable Cases (2017-2030)
  • Figure 3 : Hepatic Encephalopathy Epidemiology in the United States (2017-2030)
  • Figure 4 : Hepatic Encephalopathy Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5 : Hepatic Encephalopathy Epidemiology in Germany (2017-2030)
  • Figure 6 : Hepatic Encephalopathy Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7 : Hepatic Encephalopathy Epidemiology in France (2017-2030)
  • Figure 8 : Hepatic Encephalopathy Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9 : Hepatic Encephalopathy Epidemiology in Italy (2017-2030)
  • Figure 10 : Hepatic Encephalopathy Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11 : Hepatic Encephalopathy Epidemiology in Spain (2017-2030)
  • Figure 12 : Hepatic Encephalopathy Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13 : Hepatic Encephalopathy Epidemiology in the UK (2017-2030)
  • Figure 14 : Hepatic Encephalopathy Diagnosed and Treatable Cases in the UK (2017-2030)
  • Figure 15 : Hepatic Encephalopathy Epidemiology in Japan (2017-2030)
  • Figure 16 : Hepatic Encephalopathy Diagnosed and Treatable Cases in Japan (2017-2030)
  • Figure 17 : Drug Name, Clinical Trials by Recruitment status
  • Figure 18 : Drug Name, Clinical Trials by Zone
  • Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Figure 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Figure 22 : United States Market Size in USD, Million (2017-2030)
  • Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Figure 24 : Germany Market Size in USD, Million (2017-2030)
  • Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Figure 26 : France Market Size in USD, Million (2017-2030)
  • Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Figure 28 : Italy Market Size in USD, Million (2017-2030)
  • Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Figure 30 : Spain Market Size in USD, Million (2017-2030)
  • Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Figure 34 : Japan Market Size in USD, Million (2017-2030)
  • Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)
目次
Product Code: DIMI0099

DelveInsight's "Hepatic Encephalopathy - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Hepatic Encephalopathy, historical and forecasted epidemiology as well as the Hepatic Encephalopathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Hepatic Encephalopathy market report provides current treatment practices, emerging drugs, Hepatic Encephalopathy market share of the individual therapies, current and forecasted Hepatic Encephalopathy market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Hepatic Encephalopathy treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Hepatic Encephalopathy Disease Understanding and Treatment Algorithm

The DelveInsight Hepatic Encephalopathy market report gives a thorough understanding of the Hepatic Encephalopathy by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Hepatic Encephalopathy.

Treatment

It covers the details of conventional and current medical therapies available in the Hepatic Encephalopathy market for the treatment of the condition. It also provides Hepatic Encephalopathy treatment algorithms and guidelines in the United States, Europe, and Japan.

Hepatic Encephalopathy Epidemiology

The Hepatic Encephalopathy epidemiology division provide insights about historical and current Hepatic Encephalopathy patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Hepatic Encephalopathy epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Hepatic Encephalopathy Epidemiology

The epidemiology segment also provides the Hepatic Encephalopathy epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Hepatic Encephalopathy Drug Chapters

Drug chapter segment of the Hepatic Encephalopathy report encloses the detailed analysis of Hepatic Encephalopathy marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Hepatic Encephalopathy clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Hepatic Encephalopathy treatment.

Hepatic Encephalopathy Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Hepatic Encephalopathy treatment.

Hepatic Encephalopathy Market Outlook

The Hepatic Encephalopathy market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Hepatic Encephalopathy market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Hepatic Encephalopathy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Hepatic Encephalopathy market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Hepatic Encephalopathy market in 7MM.

The United States Market Outlook

This section provides the total Hepatic Encephalopathy market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Hepatic Encephalopathy market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Hepatic Encephalopathy market size and market size by therapies in Japan is also mentioned.

Hepatic Encephalopathy Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Hepatic Encephalopathy market or expected to get launched in the market during the study period 2017-2030. The analysis covers Hepatic Encephalopathy market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Hepatic Encephalopathy Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Hepatic Encephalopathy key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Hepatic Encephalopathy emerging therapies.

Reimbursement Scenario in Hepatic Encephalopathy

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Hepatic Encephalopathy domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Hepatic Encephalopathy market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Hepatic Encephalopathy Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Hepatic Encephalopathy, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Hepatic Encephalopathy epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Hepatic Encephalopathy are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Hepatic Encephalopathy market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Hepatic Encephalopathy market

Report Highlights

  • In the coming years, Hepatic Encephalopathy market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Hepatic Encephalopathy R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Hepatic Encephalopathy. Launch of emerging therapies will significantly impact the Hepatic Encephalopathy market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Hepatic Encephalopathy
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Hepatic Encephalopathy Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Hepatic Encephalopathy Pipeline Analysis
  • Hepatic Encephalopathy Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Hepatic Encephalopathy Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage

Hepatic Encephalopathy Epidemiology Segmentation

  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Hepatic Encephalopathy Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Hepatic Encephalopathy market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Hepatic Encephalopathy total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Hepatic Encephalopathy market size during the forecast period (2017-2030)?
  • At what CAGR, the Hepatic Encephalopathy market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Hepatic Encephalopathy market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Hepatic Encephalopathy market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Hepatic Encephalopathy?
  • What is the historical Hepatic Encephalopathy patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Hepatic Encephalopathy in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Hepatic Encephalopathy?
  • Out of all 7MM countries, which country would have the highest prevalent population of Hepatic Encephalopathy during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
  • Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
  • What are the current options for the Hepatic Encephalopathy treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Hepatic Encephalopathy in the USA, Europe, and Japan?
  • What are the Hepatic Encephalopathy marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Hepatic Encephalopathy?
  • How many therapies are developed by each company for Hepatic Encephalopathy treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Hepatic Encephalopathy treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Hepatic Encephalopathy therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Hepatic Encephalopathy and their status?
  • What are the key designations that have been granted for the emerging therapies for Hepatic Encephalopathy?
  • What are the global historical and forecasted market of Hepatic Encephalopathy?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Hepatic Encephalopathy market
  • To understand the future market competition in the Hepatic Encephalopathy market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Hepatic Encephalopathy in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Hepatic Encephalopathy market
  • To understand the future market competition in the Hepatic Encephalopathy market

Table of Contents

1. Key Insights

2. Executive Summary of Hepatic Encephalopathy

3. Competitive Intelligence Analysis for Hepatic Encephalopathy

4. Hepatic Encephalopathy: Market Overview at a Glance

  • 4.1. Hepatic Encephalopathy Total Market Share (%) Distribution in 2017
  • 4.2. Hepatic Encephalopathy Total Market Share (%) Distribution in 2030

5. Hepatic Encephalopathy: Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Hepatic Encephalopathy Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Hepatic Encephalopathy Epidemiology Scenario in the 7MM (2017-2030)
  • 7.4. United States Epidemiology
    • 7.4.1. Hepatic Encephalopathy Epidemiology Scenario in the United States (2017-2030)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Hepatic Encephalopathy Epidemiology Scenario in Germany (2017-2030)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Hepatic Encephalopathy Epidemiology Scenario in France (2017-2030)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Hepatic Encephalopathy Epidemiology Scenario in Italy (2017-2030)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Hepatic Encephalopathy Epidemiology Scenario in Spain (2017-2030)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Hepatic Encephalopathy Epidemiology Scenario in the United Kingdom (2017-2030)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Hepatic Encephalopathy Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Hepatic Encephalopathy Treatment and Management
  • 8.2. Hepatic Encephalopathy Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Hepatic Encephalopathy Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. Hepatic Encephalopathy: Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Hepatic Encephalopathy Market Size in 7MM
  • 13.3. Hepatic Encephalopathy Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Hepatic Encephalopathy Total Market Size in the United States
    • 15.1.2. Hepatic Encephalopathy Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Hepatic Encephalopathy Total Market Size in Germany
    • 15.3.2. Hepatic Encephalopathy Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Hepatic Encephalopathy Total Market Size in France
    • 15.4.2. Hepatic Encephalopathy Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Hepatic Encephalopathy Total Market Size in Italy
    • 15.5.2. Hepatic Encephalopathy Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Hepatic Encephalopathy Total Market Size in Spain
    • 15.6.2. Hepatic Encephalopathy Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Hepatic Encephalopathy Total Market Size in the United Kingdom
    • 15.7.2. Hepatic Encephalopathy Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Hepatic Encephalopathy Total Market Size in Japan
    • 15.8.3. Hepatic Encephalopathy Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Hepatic Encephalopathy

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight